Ventyx Biosciences, Inc. Q3 FY2022 earnings call

Raju Mohan provided a business update: positive Phase 1 results for VTX-958 with potential best-in-class safety and clinical differentiation; FDA approval of Bristol-Myers TYK2 inhibitor Sotyktu; completed a $176.6M private placement extending capital runway; planning a science-focused R&D Day on Jan 26, 2023. Bill Sandborn provided pipeline updates: VTX-958 on track for Phase 2 trials in psoriasis, Crohn's disease, and psoriatic arthritis in Q4 2022; VTX002 Phase 2 induction trial for ulcerative colitis with strong enrollment trends and top line data expected in 2023; VTX2735 planning a trial in CAPS and to select an additional Phase 2 indication; VTX3232 on track for Phase 1 trial in Q1 2023.

No detailed product segment financial performance with revenue contribution percentages provided. Financials noted: R&D expenses $25.5M in Q3 2022 vs $10.5M in Q3 2021, G&A expenses $6M vs $2.2M, net loss $30.5M vs $12.8M, cash, cash equivalents and marketable securities $412.4M as of Sep 30, 2022, with sufficient funds to fund operations into 2025.

Extended capital runway to over two years into 2025 from the private placement; VTX002 top line data guidance for 2023, with Phase 2 enrollment estimated complete by mid-2023; planning to initiate three Phase 2 trials for VTX-958 in Q4 2022.

Forward-looking statements subject to risks and uncertainties, with factors discussed in greater detail in the company's most recent periodic reports filed with the SEC.

Q: Michael Yee asked about differentiation of VTX-958 vs competitors and expectations for the S1P program.

A: Raju Mohan discussed molecular and clinical differentiation, Bill Sandborn addressed S1P trial design.

Q: Swapnil Malekar inquired about dosing differences for Crohn's vs psoriasis and steps to initiate Phase 2.

A: Bill Sandborn addressed dosing and initiation steps.

Q: Sam Slutsky asked about lupus indication for VTX-958, combination approaches, and new formulation of VTX-958.

A: Raju Mohan and Bill Sandborn answered on lupus, combination, and formulation.

Q: Emily Bodnar asked about Phase 2 data timeline for VTX-958 and other indications for VTX002.

A: Raju Mohan and Bill Sandborn answered on data timeline and other indications.

Q: Alex Thompson inquired about upcoming data from NIMBUS and confidence in exposure-efficacy hypothesis.

A: Raju Mohan and Bill Sandborn discussed coverage and data.

Q: Jeff Jones asked about dose titration for VTX002 and patient populations.

A: Bill Sandborn answered on dose titration and patient populations.

Q: John (Tiago Fauth) asked about selectivity of VTX002 for S1P1.

A: Raju Mohan answered on selectivity and implications.